Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$128.00K$128.00Kderived−3.8% vs Q4 2021 Net Income-$8.70M-$8.70MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$9,392,000N/M Operating Cash Flowderived-$9,390,000N/M Free Cash Flowderived-$9,465,000N/M Margins · derivedOperating margin-7337.5%−175.1 pt vs Q4 2021
Net margin-6794.5%+304.7 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 2, 2023 · 61 d after period end